Abstract
Krebs von den Lungen-6 (KL-6) levels measured at baseline have been reported as a circulating biomarker useful for the detection, evaluation of severity and assessment of risk of the progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In this retrospective study, longitudinal changes in serum KL-6 levels over 2 years were examined in 110 patients with SSc using prospectively collected cohort data. Serum KL-6 levels fluctuated in a significant proportion of the patients but remained stable in the remaining patients. A wide range of variability of longitudinal KL-6 levels was associated with the presence of ILD, diffuse cutaneous SSc, positive anti-topoisomerase I antibodies, negative anticentromere antibodies, increased ILD extent on high-resolution computed tomography, extensive disease, low pulmonary function parameters, high KL-6 levels at baseline and immunomodulatory treatment. Extensive disease was consistently identified as an independent factor associated with variability in KL-6 levels in different models of multiple regression analysis. We failed to demonstrate correlations between trends for KL-6 level changes during the 6 months after SSc diagnosis and ILD progression over 2 years in patients with SSc-ILD. Serum KL-6 levels fluctuate in SSc patients with ILD, especially in those with extensive disease, but the clinical utility of a serial KL-6 level measurement remains uncertain.
Highlights
Interstitial lung disease (ILD) is the leading cause of disease-related morbidity and mortality in patients with systemic sclerosis (SSc) [1]
Demographic and clinical features, serum biomarkers, pulmonary function test (PFT) parameters and imaging characteristics have been reported as potential risk factors for progression in patients with SSc-ILD, but the majority of these features have not been verified in independent studies [10,11]
Of the 362 patients with SSc registered in the SSc database of two hospitals, 110 patients were enrolled in this study (Supplemental Figure S1)
Summary
Interstitial lung disease (ILD) is the leading cause of disease-related morbidity and mortality in patients with systemic sclerosis (SSc) [1]. A substantial portion of patients show a progressive decline in pulmonary function, leading to end-stage lung disease (ESLD) and mortality, whereas others show stable pulmonary function during the entire course of the disease [7,8,9]. In this case, it is necessary to identify risk factors that predict a future progression of ILD early in the course of the disease. Demographic and clinical features, serum biomarkers, pulmonary function test (PFT) parameters and imaging characteristics have been reported as potential risk factors for progression in patients with SSc-ILD, but the majority of these features have not been verified in independent studies [10,11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
